Cerdulatinib hydrochloride

  Cat. No.:  DC41092  
Chemical Structure
1369761-01-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.
Cas No.: 1369761-01-2
Chemical Name: Cerdulatinib hydrochloride
Formula: C20H28ClN7O3S
M.Wt: 482.00
Sotrage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC42425 Syk-IN-4 Syk-IN-4 is a potent, selective and orally bioavailable SYK with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers.
DC42007 Syk Kinase Peptide Substrate Syk Kinase Peptide Substrate is a Syk kinase peptide substrate.
DC42006 Syk Kinase Peptide Substrate, Biotin labeled Syk Kinase Peptide Substrate, Biotin labeled is a biotin-labled Syk kinase peptide substrate.
DC41092 Cerdulatinib hydrochloride Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.
DC40367 Syk-IN-1 Syk-IN-1 (compound 4) is a potent Syk inhibitor, with an IC50 of 35 nM.
DC28255 Lanraplenib succinate Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
DC28254 Lanraplenib monosuccinate Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
X